简介:目的探讨PIAS3过表达对人脑胶质瘤U251细胞生长的作用及其可能的机制.方法通过实时荧光定量PCR检测PIAS3在正常脑细胞和脑胶质瘤U251细胞中的表达情况.转染PIAS3过表达载体,提高U251细胞中PIAS3表达水平,通过噻唑蓝(MTT)试验检测细胞增殖情况.WesternBlot验证PIAS3表达与增殖相关基因PI3K及Akt间关系.结果PIAS3在正常脑组织中相对高表达,而在人脑胶质瘤U251细胞中表达明显下降(P<0.01).体外转染PIAS3过表达载体能明显抑制U251细胞生长,并且有效抑制PI3K活性及p-Akt表达,但对总的Akt无明显影响.结论胶质瘤U251细胞中异常低表达的PIAS3发挥着重要的增殖促进作用,过表达PIAS3可通过抑制PI3K/Akt通路有效抑制U251细胞增殖.
简介:目的研究RNA干扰下调核因子E2相关因子2(Nrf2)对U251细胞自噬的影响.方法建立RNA干扰下调Nrf2表达的U251细胞系并在瞬时转染48h后,电镜观察细胞自噬相关结构的形态,Westernblot法、吖啶橙染色流式细胞术定量分析自噬水平的改变.结果与对照组相比,Si-Nrf2组Nrf2的蛋白水平明显下降(P<0.001),自噬泡结构增多,微管相关蛋白1轻链蛋白3BII型(LC3B-Ⅱ)的蛋白水平明显升高(P<0.001),酸性囊泡数量明显增多(P<0.05).结论RNA干扰下调Nrf2可以显著增强U251细胞的自噬水平.
简介:Thequestforneuroprotectivedrugstoslowtheprogressionofneurodegenerativediseases(NDDs),includingAlzheimer'sdisease(AD),Parkinson'sdisease(PD),andHuntington'sdisease(HD),hasbeenlargelyunrewarding.Preclinicalevidencesuggeststhatrepurposingquetiapine,lithium,valproate,fluoxetine,donepezil,andmemantineforearlyandpre-symptomaticdisease-modificationinNDDsmaybepromisingandcanspareregulatorybarriers.Theliteratureofthesepsychotropicsinearlystageandpre-symptomaticAD,PD,andHDisreviewedandpropitiousfindingsfollow.Mildcognitiveimpairment(MCI)phaseofAD:salutaryhumanrandomizedcontrolledtrialfindingsforlow-doselithiumand,inselectedpatients,donepezilawaitreplication.Pre-symptomaticAD:humanepidemiologicaldataindicatethatlithiumreducesADrisk.Animalmodelstudies(AMS)revealencouragingresultsforquetiapine,lithium,donepezil,andmemantine.EarlyPD:valproateAMSfindingsshowpromise.Pre-symptomaticPD:lithiumandvalproateAMSfindingsareencouraging.EarlyHD:uncontrolledclinicaldataindicatenon-progressionwithlithium,fluoxetine,donepezil,andmemantine.Pre-symptomaticHD:lithiumandvalproateareauspiciousinAMS.Manyotherpromisingfindingsawaitingreplication(valproateinMCI;lithium,valproate,fluoxetineinpre-symptomaticAD;lithiuminearlyPD;lithium,valproate,fluoxetineinpre-symptomaticPD;donepezilinearlyHD;lithium,fluoxetine,memantineinpre-symptomaticHD)arereviewed.Dose-andstage-dependenteffectsareconsidered.Suggestionsforsignal-enhancementinhumantrialsareprovidedforeachNDDstage.
简介:Neurotrophicfactorscompriseessentialsecretedproteinsthathaveseveralfunctionsinneuralandnon-neuraltissues,mediatingthedevelopment,survivalandmaintenanceofperipheralandcentralnervoussystem.Therefore,neurotrophicfactorissuehasbeenextensivelyinvestigatedintothecontextofneurodegenerativediseases.Alzheimer'sdiseaseandParkinson'sdiseaseshowchangesintheregulationofspecificneurotrophicfactorsandtheirreceptors,whichappeartobecriticalforneuronaldegeneration.Indeed,neurotrophicfactorspreventcelldeathindegenerativeprocessesandcanenhancethegrowthandfunctionofaffectedneuronsinthesedisorders.Basedonrecentreports,thisreviewdiscussesthemainfindingsrelatedtotheneurotrophicfactorsupport–mainlybrain-derivedneurotrophicfactorandglialcellline-derivedneurotrophicfactor–inthesurvival,proliferationandmaturationofaffectedneuronsinAlzheimer'sdiseaseandParkinson'sdiseaseaswellastheirputativeapplicationasnewtherapeuticapproachforthesediseasesmanagement.
简介:目的利用RNA干扰(RNAinterference,RNAi)技术特定沉默胶质瘤U251细胞株的血小板源生长因子-B(PDGF-B)基因,观察其对U251细胞株细胞凋亡和增殖的影响。方法利用脂质体将针对PDGF-B基因的siRNA转染进入U251细胞,利用实时荧光定量多聚核苷酸链式反应(RTPCR)检测PDGF-B基因表达;Westernblot检测显示siRNA转染组PDGF-B蛋白表达,采用MTT法检测胶质瘤U251细胞的增殖,应用流式细胞计数观察抑制PDGF-B基因后胶质瘤U251细胞的凋亡情况。结果RT-PCR检测PDGF-B基因表达明显下降;Westernblot检测显示siRNA转染组PDGF-B蛋白表达明显抑制(抑制率〉60%),MTT结果显示siRNA转染组U251细胞增殖较对照组明显降低;流式细胞学检测提示降低PDGF-B在胶质瘤细胞的表达能抑制胶质瘤细胞的有丝分裂,促进细胞的凋亡。结论构建针对胶质瘤细胞PDGF-B的RNA干扰质粒并转染人胶质瘤U251细胞株后,可明显抑制U251细胞株PDGF的表达,对人胶质瘤U251细胞株有明显的生长抑制和促进凋亡作用。
简介:目的构建表达靶向抑制survivin基因的三个短发夹结构(shRNA)的RNA干扰载体,使其在胶质瘤细胞发挥干扰效应。方法在survivin全长序列中选取设计3条19个核苷酸靶序列,2条反向重复序列,间以9个核苷酸的茎环序列,加上对应酶切位点,形成3条shRNA的DNA模板,分别克隆到3个干扰载体pG1,pG2和pG3上;采用分布酶切连接的方法,分别将U6启动子以及下游的后2个shRNA模板酶切下来,依次连接到pG1对应酶切位点,构建出含有3条shRNA模板且能独立编码shRNA的重组干扰载体pGenesil-survivin,测序鉴定;将干扰质粒导入到胶质瘤细胞U251,分别采用RT-PCR以及WesternBloting从mRNA和蛋白水平检测干扰后效果。结果重组的干扰载体含有3条正确的shRNA模板:RT-PCR以及WesternBlotting检测显示,survivin的mRNA转录水平以及蛋白水平的表达均得到显著抑制。结论编码3条shRNA的干扰载体pGenesil-survivin介导的RNA干扰技术(RNAi)可以显著的靶向抑制survivin基因在人胶质瘤细胞U25l中的表达。
简介:目的MSP58是一种能够通过调节基因的转录和翻译水平来改变细胞恶性表型的癌基因,其蛋白的分子量大小为58kDa。但截止目前,其在肿瘤发生及发展中所起的作用仍不是十分清楚。我们通过构建MSP58基因的干涉表达载体,下调MSP58基因在人脑胶质瘤细胞系U251中的表达以揭示其在胶质瘤增殖、迁移和侵袭中所起的作用。方法将特异性的MSP58干涉表达载体pSilencer3.1-MSP58转染人脑胶质瘤细胞系U251,同时构建相应的阴性对照载体pSilencer3.1-NC以及空载体pSilencer3.1-H1neo。运用半定量RT-PCR及Westernblot的方法检测稳定转染和未转染干涉载体的胶质瘤细胞的MSP58的mRNA和蛋白的表达水平。运用MTT法测定胶质瘤细胞的增殖水平。流式细胞仪检测细胞周期变化以及单层细胞划痕试验和侵袭小室试验检测胶质瘤细胞的迁移及侵袭能力变化。结果成功建立了三种稳定转染细胞株:分别是具有稳定下调MSP58基因表达的U251-S细胞,阴性对照U251-NC细胞以及含有空载体的u251.H1neo细胞。干涉组细胞的MSP58的表达水平无论在mRNA水平还是在蛋白水平均较阴性对照组及空载体组细胞显著降低。其表达抑制率分别为62.7%和60.3%。干涉组细胞的增殖能力明显降低。同时在细胞周期方面,干涉组细胞与阴性对照组及空载体组细胞相比,发生了显著的G1期阻滞。细胞迁移及侵袭试验结果显示,MSP58干涉组的细胞较其他对照组细胞的迁移及侵袭能力均受到明显抑制。结论通过RNA干涉的方法下调MSP58基因的mRNA和蛋白的表达,不但可以明显的抑制人脑胶质瘤细胞的增殖,并且可以显著的抑制胶质瘤细胞的迁移及侵袭能力。因此,靶向性MSP58基因RNAi介导的胶质瘤基因治疗具有良好的应用前景。
简介:BACKGROUND:Itisdifficulttoattractinterestinnon-compulsory,preventive,medicalcare,andpersonsdiagnosedwithcertaindiseasesoftenignoretheexistenceofthesediseases.However,Huntington'sdisease(HD)isanexception.OBJECTIVE:ToqualitativelyanalyzefactorsmotivatingHDpatientstoparticipateinastudy,namelytheEuropeanHuntington'sDiseaseNetwork(EHDN)REGISTRY.DESIGN,TIMEANDSETTING:AnobservationalsurveywasconductedintheEHDNStudySiteinPoznan,Polandbetween2007and2008.PARTICIPANTS:Thestudyinvolved22personsaffectedwithHDand3pre-symptomaticindividuals,totaling9malesand16females.The24participantsinthisstudyhad24differentcaregivers.Atotalof25symptomaticorpre-symptomaticsubjectsparticipatedintheinitialREGISTRYvisit,aswellas6inthesecond,and1inthethird.Allsubjectsdidnotknoweachotherpriortothevisit.METHODS:AmutationintheIT15genewasconfirmedineachpatientorpre-symptomaticmutationcarrier.Anin-depthinterviewproduceddetailedinformationontheHDpatients,aswellasthecaregivers,fortheREGISTRYstudy.MAINOUTCOMEMEASURES:AqualitativeanalysisofthefactorsmotivatingHDpatientsandthepre-symptomaticmutationcarrierstoparticipateintheREGISTRYlongitudinal,observational,researchprojectwasperformed.RESULTS:TheprimarymotivatingfactorforinvolvementofHDpatientsandthecaregiversintheREGISTRYstudywasthehopethataneffectiveHDtherapywouldsoonbediscovered.InHDpatientsandthepre-symptomaticgroup,theresponsetoparticipateintheREGISTRYprojectreached100%,despitethefactthattheyknewtheprojectwasonlyanobservationalstudy.CONCLUSION:Patienthopeisthoughttobeafactorforengaginginpreventive,therapeuticactivities.However,thisisrarelymentionedinmedicalpapersandclinicaltextbooks,andisusuallyoverlookedinmedicalteaching.Clearly,effortsshouldbemadetoincludethisinclinicalpractice.
简介:目的探讨三氧化二砷(As2O3)对人胶质瘤U251细胞的生长及端粒酶活性的影响。方法采用倒置显微镜和透射电镜观察As2O3处理后U251细胞形态变化;四甲基偶氮唑蓝比色法观察As2O3对U251细胞增殖的影响;流式细胞术检测细胞凋亡;端粒重序列扩增酶联免疫吸附实验(TRAP-ELISA)结合聚丙烯酰胺凝胶电泳(TRAP-PAGE)银染法检测As2O3处理后U251细胞端粒酶活性变化。结果倒置显微镜下观察到:As2O3处理后的U251细胞逐渐变圆、脱壁,细胞间接触变松,细胞质中颗粒增多,增殖变慢,细胞周围碎片增多;透射电镜下见较多典型凋亡细胞。1~8μmol/LAs2O3明显抑制U251细胞增殖,诱导其凋亡;并使端粒酶活性逐渐下降,该作用呈浓度和时间依赖性。结论As2O3对人胶质瘤U251细胞株生长具有显著抑制作用,其机制可能与As2O3能够抑制U251细胞的端粒酶活性密切相关。
简介:目的探讨Evi1基因在不同级别胶质瘤组织中的表达,以及调控该基因对胶质瘤细胞株U87和U251细胞增殖、细胞周期和侵袭影响,为靶向癌基因治疗胶质瘤提供客观依据。方法首先通过实时定量PCR(qRT-PCR)分别检测人脑不同级别胶质瘤组织以及U87和U251细胞株中Evil基因的表达水平。用合成的小分子干扰RNA(smallinterferingRNA,siRNA)干扰下调U87和U251细胞Evi1基因表达作为干扰组,同时设空白和阴性对照组。qRT-PCR检测转染前后Evi1基因在U87和U251细胞中的表达和转染效率。CCK-8法检测实验组细胞的增殖能力,流式细胞仪分析FlowCytometer(FCM)其细胞周期。Transwell以及划痕试验检测各组U87和U251的侵袭和迁移能力。以及用qRT-PCR分析下调Evi1基因后U87和U251细胞基质金属蛋白酶2(MMP2)的表达水平。结果Evi1基因在胶质瘤组织中呈现高表达,且随着胶质瘤级别程度增加其表达水平亦上升,其中Ⅲ和Ⅳ级的胶质瘤组织以及U87、U251细胞Evi1基因表达明显高于非瘤脑组织(均P〈0.05)。通过siRNA下调Evi1基因后,胶质瘤细胞株U87和U251的增殖减缓(均P〈0.05),其侵袭和迁移能力明显下降(均P〈0.01),并能阻滞其细胞周期G1期(P〈0.05)。干扰组U87和U251细胞MMP2表达水平明显降低(均P〈0.01)。结论Evi1基因在胶质瘤中呈高表达,干扰U87和U251细胞Evi1基因可抑制胶质瘤的增殖和侵袭。
简介:Parkinsonsdisease(PD)isacommon,progressiveneurodegenerativediseasecharacterisedbydegenerationofnigrostriataldopaminergicneurons,aggregationofα-synucleinandmotorsymptoms.Currentdopamine-replacementstrategiesprovidesymptomaticrelief,howevertheireffectivenesswearoffovertimeandtheirprolongeduseleadstodisablingside-effectsinPDpatients.ThereisthereforeacriticalneedtodevelopnewdrugsanddrugtargetstoprotectdopaminergicneuronsandtheiraxonsfromdegenerationinPD.Overrecentyears,therehasbeenrobustevidencegeneratedshowingthatepigeneticdysregulationoccursinPDpatients,andthatepigeneticmodulationisapromisingtherapeuticapproachforPD.Thisarticlefirstdiscussesthepresentevidenceimplicatingglobal,anddopaminergicneuron-specific,alterationsinthemethylomeinPD,andthetherapeuticpotentialofpharmacologicallytargetingthemethylome.Itthenfocusesonanothermechanismofepigeneticregulation,histoneacetylation,anddescribeshowthehistoneacetyltransferase(HAT)andhistonedeacetylase(HDAC)enzymesthatmediatethisprocessareattractivetherapeutictargetsforPD.Itdiscussestheuseofactivatorsand/orinhibitorsofHDACsandHATsinmodelsofPD,andhowtheseapproachesfortheselectivemodulationofhistoneacetylationelicitneuroprotectiveeffects.Finally,itoutlinesthepotentialofemployingsmallmoleculeepigeneticmodulatorsasneuroprotectivetherapiesforPD,andthefutureresearchthatwillberequiredtodetermineandrealisethistherapeuticpotential.
简介:Propofolcaninhibittheinflammatoryresponseandreducethesecretionandharmfuleffectsofastrocyte-derivedproinflammatorycytokines.Inthisstudy,afterpropofolwasinjectedintotheinjuredsciaticnerveofmice,nuclearfactorkappaBexpressionintheL4-6segmentsofthespinalcordintheinjuredsidewasreduced,apoptosiswasdecreased,nervemyelindefectswerealleviated,andthenerveconductionblockwaslessened.Theexperimentalfindingsindicatethatpropofolinhibitstheinflammatoryandimmuneresponses,decreasestheexpressionofnuclearfactorkappaB,andreducesapoptosis.Theseeffectsofpropofolpromoteregenerationfollowingsciaticnerveinjury.
简介:目的探讨应用RNA干涉(RNAi)技术抑制U251恶性胶质瘤细胞丝/苏氨酸蛋向激酶1(AKT1)和3-羧基磷脂酰肌醇激酶的85000催化亚基(P13KP85)表达后对U251胶质瘤细胞侵袭的抑制作用.方法实验设正常对照组(未做任何处理);阴性对照组(rAd-HK组):用无义序列重组腺病毒感染U251胶质瘤细胞;基凶治疗组(rAd-A+P组):用靶向AKT1和P13KP85的重组腺病毒感染U251胶质瘤细胞.应用实时PCR检测AKT1和P13KP85mRNA水平的变化;应用Westernblot方法检测AKT1和P13KP85蛋白水平的变化,并对肿瘤细胞中相关功能蛋白的表达进行分析;应用酶联免疫分析法(ELISA)检测细胞外基质金属蛋白酶2(MMP2)和基质金属蛋白酶9(MMP9)浓度的变化;应用划痕和Transwell实验评价肿瘤细胞侵袭能力的变化.结果tAd-A+P可显著抑制U251胶质瘤细胞AKT1和P13KP85的表达.与正常对照组和rAd-HK组比较.rAd-A+P组MMP2、MMP9表达下降,而基质金属蛋白酶抑制因子(TMP2)表达上调,差异有统计学意义(P〈0.05).划痕和Transwell实验显示rAd-A+P组细胞体外侵袭能力明显减弱.结论靶向AKT1和P13KP85的RNAi技术可以显著抑制U251胶质瘤细胞AKT1和PDKP85表达,对U251胶质瘤细胞的侵袭能力产生明显抑制作用.
简介:目的比较O-(氯乙酰-氨甲酰基)炯曲霉醇(TNP-470)和卡氮芥(BCNU)对人U-251胶质母细胞瘤细胞裸鼠皮下移植瘤的治疗作用。方法将人U-251胶质母细胞瘤细胞株种植于裸鼠皮下,制备U-251胶质瘤动物模型,第7天荷瘤裸鼠随机分为3组:TNP-470组、BCNU组及对照组。治疗后第21天观察裸鼠体重及肿瘤大小,并测定移植瘤CD105标记的肿瘤微血管密度(CD105-MVD)。结果治疗后第21天①TNP-470组(576.10mm^3±114.29mm^3)及BCNU组移植瘤体积(473.01mm^3±48.04mm^3)均明显小于(P〈0.01)对照组(1512.61mm^3±470.25mm^3);TNP-470组与BCNU组间移植瘤体积无显著性差异(P〉0.05)。②TNP-470组与BCNU组抑瘤率分别为(61.91%±6.29%)和(68.73%±9.65%),两组相较无明显差异(P〉0.05),③TNP-470组移植瘤CD105-MVD[(5.70±0.85)个/视野]显著低于(P〈0.05)BCNU组[(8.60±0.87)个/视野];两治疗组移植瘤CD105-MVD均较对照组[(11.32±1.50)个/视野]显著降低(P〈0.05)。结论TNP-470和BCNU对人U-251胶质母细胞瘤细胞裸鼠皮下移植瘤的生长具有相同的抑制作用。
简介:BACKGROUND:ToevaluatethequalityoftheliteratureaddressingtraditionalChinesemedicinefortreatingParkinson'sdisease.DATASOURCE:Acomputer-basedonlinesearchofChinesepublicationsfromJanuary2001toJuly2008wasconductedinChineseBiologyMedicalDiscDatabaseandChinaNationalKnowledgeInfrastructure.SearchkeywordswereParkinson'sdisease,integratedtraditionalChineseandWesternmedicine,traditionalChinesemedicinetherapy,andChineseherbtherapy.DATASELECTION:Articlesdescribingrandomized,controlledtrialsandquasi-randomized,controlledtrialswereincluded.Literaturequalitywasassessedusingthecriteria-SystematicevaluationofclinicalliteraturerelatedtotreatmentofParkinson'sdiseasewithtraditionalChinesemedicine.Thisincludedmethodology,interventionsinthetreatment/controlgroup,evaluationcriterionofoutcomes,andfrequency.MAINOUTCOMEMEASURES:Evaluationcriterionofoutcomes(variousscoremethodsandevaluationscales),methodologicalquality,andfrequencydistributionwereallmeasured.RESULTS:Atotalof33articleswithrandomized,controlledtrialswereincluded.Ofthese,sixdescribedarandommethod,andtheremainingdidnotdescriberandomallocationmethodsorrandomsequencegenerationmethods.Noneofthestudiesestimatedsamplesize.Casedescriptionsofwithdrawalandlosstofollow-upwereunclear.BoththeUnifiedParkinson'sDiseaseRatingScaleandWebsterscalewereusedintheeligiblestudiesasevaluationcriteria.CONCLUSION:Therearenohigh-qualitystudiesthataddresstraditionalChinesemedicinetherapyandintegratedtraditionalChineseandWesternmedicinefortreatingParkinson'sdiseaseinChina.EligiblestudieswerenotperformedinaccordancewithConsolidatedStandardsofReportingTrialsstatementorStandardsforReportingInterventionsinControlledTrialsofAcupuncturecriteria,andtheliteraturequalitywaslow.ThepresentlyusedcriteriaforevaluatingtherapeuticeffectsdonotcompletelyassessoutcomesoftraditionalCh
简介:Parkinson’sdisease(PD)isanage-relatedneurodegenerativedisordercharacterizedbytypicalmotorsignsandsymptomsthatareduetodopamine(DA)depletioninthebasalganglia.ThetreatmentofPDissymptomatic,andaimsatreplacingthelostDAinputusingeitherL-DOPAorDAagonists.ThecausesofPDareunknownin